Clinical study on the sedative effect of remazolam in bronchoscopy in patients with mechanical ventilation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090588

Enrollment

Unknown

Registered

2024-10-09

Start date

2022-01-14

Completion date

Unknown

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory failure

Interventions

experimental group:Use remazolam for sedation

control group:Use midazolam for sedation

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1Age 18-75 years old, regardless of gender, with respiratory failure admitted to the intensive care department for invasive mechanical ventilation and requiring fiberoptic treatment.

Exclusion criteria

Exclusion criteria: 1.Severe hypoxemia (oxygenation index < 100); 2.Left ventricular ejection fraction < 30%, heart rate < 50 beats /min, degree ? ~ ? atrioventricular block; 3.Unstable angina or acute myocardial infarction; 4.Glasgow Coma Score (GCS) =8 points; 5.Patients with neuromuscular block; 6.Pregnant and lactating women; 7.Suffering from mental illness or chronic use of drugs or addictions to treat mental illness; 8. Long-term use of sedative drugs.

Design outcomes

Primary

Measure	Time frame
Sedation success rate;	—

Secondary

Measure	Time frame
Time of onset of sedation;Duration of operation;Recovery time;BPS Pain Behavior Scale score;Security;	—

Countries

China

Contacts

Public ContactJiading Xia

Affiliated Hospital of Chengde Medical University

bayer_525@163.com+86 187 3247 6024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026